Afleveringen
-
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, Dr. Grace Walker, Co-founder and Chief Regulatory Officer at Tautoko Technology discusses her work in developing a patch insulin pump with wraparound support and education software to improve diabetes management.
One of Tautoko Technology's main goals is ensuring their device is accessible to all, so that it gets into the hands of those that need it most.
You can find out more about Dr. Grace Walker and Tautoko Technology here: https://www.linkedin.com/in/gracewalkernz/
Tautoko Technology - LinkedIn
Dr Grace Walker - LinkedIn
Podcast Takeaways:
Tautoko Tech is developing a patch insulin pump with support software to improve diabetes management.The company aims to make the device more accessible by offering the pump for free and charging for the consumables.Rural communities face challenges in accessing healthcare, and Tautoko Tech's solution aims to bridge the gap.The team is driven by the desire to make a difference and improve the lives of people with diabetes.Tautoko Techs plans to raise the funds required to bring their MVP to market.They are working on getting regulatory pre-submission ready and filing a patent for their next version, and then will proceed with hotel trials and clinical trials.Chapters:
00:00 Introducing Grace Walker and Tautoko Technology
01:05 The Problem Tautoko Tech is Solving
03:50 Dr. Grace Walker's Journey and Passion
06:58 The Impact of Diabetes on Rural Communities
13:15 Making Diabetes Care More Accessible
18:45 Discussing the Tautoko Tech Team
20:17 Current Project and Future Plans
22:08 Navigating the Regulatory Pathway
26:50 Considering Biocompatibility and User Experience
29:03 Accuracy and Claims
34:58 Plans for Pitching and Funding
39:10 Advice to Aspiring Entrepreneurs -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this episode, Professor Grant Searchfield, Head of Audiology at The University of Auckland and Founder and Scientific Director of TrueSilence Therapeutics, discusses the development of a non-invasive polytherapeutic method for the treatment of Tinnitus. The method combines sound therapy, perceptual training, and psychological interventions alongside the support of machine learning to provide a personalised multifaceted approach to helping individuals with Tinnitus.
You can find out more about Prof Searchfield and TrueSilence Therapeutics here: Professor Grant Searchfield - LinkedIn
True Silence Therapeutics
Podcast Takeaways:
Tinnitus is a common complaint affecting millions of people worldwide.2. Current treatments for tinnitus have been limited in their effectiveness.3. Tinnitus is a network problem, involving multiple parts of the auditory system and brain.4. Personalised and tailored treatments are important for addressing individual differences in tinnitus.5. The use of biosensors and artificial intelligence shows promise in optimising treatment outcomes.Chapters:
00:00 Introduction and Background
03:12 Understanding Tinnitus as a Network Problem
05:04 Exploring Treatment Approaches for Tinnitus
09:43 The Importance of Personalized and Tailored Treatments for Tinnitus
13:33 The Potential of Biosensors and Artificial Intelligence in Tinnitus Treatment
𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:
tinnitus, treatment, non-invasive, auditory system, brain, sound therapy, perceptual training, psychological interventions, personalised treatment, biosensors, artificial intelligence
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases Please share with your friends and family. Also don't forget to like, subscribe, and hit the notification bell to notify you if I post a new video. Much love and God bless -
Zijn er afleveringen die ontbreken?
-
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this epsiode, Dr. Xuxu Amoozegar-Montero, founder of Uuna, discusses the problems with traditional bras and the innovative solution her company is developing. Uuna uses 3D scanning and knitting technology to create custom-fit bras that address issues of comfort, sizing inconsistency, and sustainability. The company is initially targeting the post-surgery market and plans to expand to a general market in the future.
Dr. Amoozegar-Montero emphasizes the importance of understanding and working with the end user, networking, and perseverance in entrepreneurship.
Podcast Takeaways:
Traditional bras have numerous problems, including discomfort, inconsistent sizing, and unsustainable manufacturing.Uuna Studio uses 3D scanning and knitting technology to create custom-fit bras that address these issues.The company is initially targeting the post-surgery market and plans to expand to a general market in the future.Understanding and working with the end user, networking, and perseverance are key in entrepreneurship.Timestamps:
00:00 Introduction
03:00 Introducing Oona Studio
06:00 The Inspiration for Custom-Fit Bras
09:00 The Solution: 3D Scanning and Knitting
12:00 Targeting the Post-Surgery Market
14:30 The Role of KiwiNet and Te Tukimata Ora
19:00 Expanding Skillset and Thinking Long-Term
23:00 The Future of Oona Studio
30:00 Advice for Entrepreneurs
33:00 Where to Find More Information
Keywords
bras, 3D scanning, 3D knitting, custom-fit, sizing, comfort, sustainability, post-surgery market, general market, networking, perseverance -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
In this epsiode, Dr. Vickie Shim, a Senior Research Fellow at the Auckland Bioengineering Institute, discusses her work in neuromechanics and its application to injury and degenerative diseases, specifically mild traumatic brain injury (TBI). She explains that neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts, and the potential damage that can occur.
Dr. Shim's research involves studying the brains of high school rugby players throughout a season to track brain changes and correlate them with head impacts. The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.
Podcast Takeaways:
Neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts.Mild traumatic brain injury (TBI) is a common form of TBI, with about 80% of all TBIs falling into the mild range.Repetitive head impacts, such as those experienced in contact sports or by combat soldiers, can lead to long-term brain degenerative changes and increased risk of neurodegenerative diseases.Dr. Shim's research involves studying the brains of high school rugby players to track brain changes over a season and correlate them with head impacts.The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.
Timestamps:
00:00 Introduction to Neuromechanics and Dr. Vickie Shim's Research
01:22 Understanding Brain Tissue Response to Mechanical Impact
06:22 The Prevalence and Impact of Mild Traumatic Brain Injury
10:06 Tracking Brain Changes in High School Rugby Players
19:04 Developing an AI-Based Tool for Predicting Recovery Trajectories 2
6:40 Personalized Treatment Plans for Mild Traumatic Brain Injury -
Today’s guest is Dr Maddie White, Translational Scientist and Strategic Partnerships Manager at the Gillies McIndoe Research Institute in Wellington, New Zealand.
This episode is brought to you by SAPRO Consulting.
Dr. Maddie White, a translational scientist and strategic partnerships manager at Gillies-McIndoe Institute, discusses the role of translational scientists in moving research from the lab to real-world impact. She emphasizes the importance of translating academic ideas into commercially viable products or services.
Dr. White shares her personal journey into translational science and highlights the need for more awareness and education about career opportunities in this field. She also discusses a specific project she is involved in, developing a topical cream for the treatment of vascular birthmarks in infants.
Dr. White emphasizes the need for talent, infrastructure, and funding to drive the success of translational science in New Zealand.
You can find out more about Dr White and The Gillies McIndoe Research Institute here:
LinkedIn - Maddie White
Website - Gillies McIndoe Research Institute
Podcast Takeaways:
Academic ideas need to be translated into commercially viable products or services to have a meaningful impact.A "translational scientist" is someone who takes scientific ideas from the lab and translates them into real-world products or services.Translational scientists play a crucial role in moving research from the lab to real-world impact.There is a need for more awareness and education about career opportunities in translational science.Talent, infrastructure, and funding are essential for the success of translational science. Partnerships between academia and industry are key in driving the translation of research into practical applications.
Chapters
00:00 Introduction to Translational Science
01:00 Translating Academic Ideas into Real-World Impact
08:04 Overcoming Stigma and Misconceptions
13:18 The Importance of Money in Translational Science
19:49 Creating Collaborative Networks for Impactful Research
23:58 Developing a Topical Cream for Vascular Birthmarks
26:21 Partnerships for Bringing Research to Market
Keywords:
Translational science, research, lab, real-world impact, commercialization, academic, funding, talent, infrastructure, money, partnerships, topical cream, vascular birthmarks -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
Today’s guest is Dr Victor Dieriks, the Head of the Apha Synuclein Lab at the Centre for Brain Research at the University of Auckland. Dr Dieriks studies the role of alpha synuclein in the development of Parkinson's Disease and Multiple System Atrophy (MSA).
Parkinson’s disease (PD) is currently the fastest-growing chronic neurological disorder globally. An estimated 12 million people are living with PD, with around 12,000 of those residing in New Zealand.
Unfortunately, no treatments presently target the underlying mechanisms of PD, and clinical studies aimed at discovering disease-modifying medications are limited. This means that a truly effective, curative treatment remains years away. However, numerous interventions are available today that can significantly improve the quality of life for those with PD.
Dr Victor Dieriks has two active projects with Te Titoki Matora, MedTech Research Translator
Project #1: Developing a more New Zealand-centric approach to the management and treatment of Parkinson's disease. Dr Dieriks emphasizes the importance of actively involving patients and understanding their priorities, rather than solely relying on the perspectives of healthcare professionals and researchers.Patients1 with PD often express their desire for improved dignity and quality of life, rather than just a focus on a cure or restoring mobility.Project #2: involves the use of tears (eye fluid) as a potential biofluid source for detecting Parkinson's disease biomarkes. Tears are a relatively pure and stable biological fluid, making them a promising target for developing a non-invasive diagnostic test that can be easily obtained. A core aspect of this project is reducing the burden on the healthcare system, particularly the long wait times to see a neurologist for diagnosis. By developing a simple, tear-based test, patients can potentially bypass the need for more invasive procedures and receive earlier prognosis and treatment.Podcast Takeaways:
Parkinson's disease is not a single disease, but rather a collection of diseases with multiple causesThe normal function of alpha-synuclein is not fully understood, but it is known to play a role in neuronal communication and potentially in the gut and microbiomeCurrent treatments for Parkinson's, like levodopa and deep brain stimulation, only address the symptoms and cannot stop the underlying disease progressionA major challenge is that current therapies are tested too late, only after 70% of the relevant neurons have already died.Early detection is key, and recent breakthroughs have shown that alpha-synuclein clumps can be detected in spinal fluid or even potentially in less invasive samples like skin or nasal swabs, years before symptom onsetWhile genetic risk factors can be screened for, they only account for a small percentage of Parkinson's cases. Other risk factors include environmental exposures like metals, pesticides, and viral/bacterial infections that cause inflammationIn the absence of a cure, lifestyle interventions like exercise, healthy eating, and moderate coffee consumption can help delay the onset and progression of Parkinson's. Exercise, in particular, has been shown to have neuroprotective effects mediated by the hormone irisin.The gut-brain axis is also implicated in Parkinson's, with constipation and other gut symptoms often preceding the motor symptoms.Chapters
0:00 Introduction
01:10 "Parkinson's Disease" is a misnomer
02:50 Dieriks Lab Focus
06:00 Peculiarities of Neurodegenerative Diseases
09:00 Role of alpha synuclein
14:00 Treatment's available for Parkinson's Disease
19:00 Risk factors for Parkinson's Disease
24:00 Alternative sampling methods for determining risk of
PD 27:20 Interventions for slowing development
31:00 Coffee
32:12 Gut-brain Axis
35:25 New Zealand-centric approach to management and treatment of PD 39:00 Importance of having all stakeholders engaged
44:30 Tears can predict risk of Parkinson's Disease?
Keywords: Parkinson's Disease, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.
Early Detection of Parkinson's Diseases | Dr Victor Dieriks | TTM Ep02 -
Today’s guest is Dr Haruna Suzuki-Kerr, Research Fellow at the University of Auckland in the Auditory & Vestibular Translational Neuroscience Cluster.
This episode is part of the Te Titoki Mataora Podcast Series, in collaboration with Te Titoki Mataora, the MedTech Research Translator.
Hearing loss is a common problem, in fact 1 in 6 people experience some form of hearing loss. Broadly speaking, hearing loss can be broken down into conductive hearing loss - think glue ear or damage to the ear drum - or sensorineural hearing loss (SNHL). SNHL is the most common type of hearing loss, and is caused by a pathology of the cochlea, auditory nerve, or central nervous system.
The problem - the inner ear apparatus is embedded deep within the skull, is very small, and thus is very difficult to study.
Enter Dr Haruna Suzuki-Kerr. Haruna and her team, with seed funding fro m Te Titoki Mataori, are developing a novel, non-invasive, light-based, medical technology and device for the investigation of the 1) structure and 2) chemistry of the inner ear.
To date Haruna and her team have assembled a multi-disciplinary team to inform the design of their medical device and increase the likelihood of commercial success. The initial proof of concept will be tested in sheep tissue, before moving into live sheep model, and then into man!
Chapters
00:00 Introduction and Background
02:00 The Different Types of Hearing Loss
04:50 Architecture of the Inner Ear
07:00 Studying Sensorineural Hearing Loss
11:00 Haruna's previous research experience and Holy Grail of this project
14:30 Inception of the Idea and Design
18:00 Why use light-based techniques?
22:30 Current Status of the Project
28:00 Commercialization Journey and TTM support
36:00 Next Steps for the Project and the ultimate goal
Keywords: hearing loss, sensorineural hearing loss, medical device, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.
Using Light to Elucidate the Secrets of the Inner Ear | Dr Haruna Suzuki-Kerr | TTM Ep02 -
Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.
Te Titoki Mataora (TTM) is a New Zealand-based organization focused on translating basic science into real outcomes in healthcare.
Here to provide an background to Te Titoki Mataora, the current framework to support research translation and some forward thinking perspectives is Distinguished Professor Sir Peter Hunter.
After identifying a need to translate basic science into real outcomes in healthcare Sir Peter Hunter and Di Siew founded the Consortium for Medical Device Technologies (CMDT). Over years this resulted in the spin out of a number of companies, as well as a bid for a MedTech Centre of Research Excellence (CoRE), and more recently Te Titoki Mataora, the MedTech Research Translator.
Te Titoki Mataora aims to develop a New Zealand-wide approach to medical technology translation by collaborating with universities, Callaghan Innovation, and the healthcare system. Supported by the Ministry of Business Innovation and Employment (MBIE) and the University of Auckland, the organization provides funding and support through programs like the Research Acceleration Program (RAP) to help researchers and spin-out companies progress from ideation to commercialization. TTM has already funded 69 projects and aims to create more high-paying jobs and successful medtech companies in New Zealand.
In Sir Peter's Words, "I don't see any reason why we can't be creating, over the next 10 years, another ten Fisher and Paykel Heathcares".
Keywords
Te Titoki Mataora, TTM, Consortium for Medical Device Technologies, CMDT, medical technology, translation, New Zealand, research acceleration program, RAP, spin-out companies, funding, high-paying jobs, medtech ecosystem
Sound Bites
"Te Taitoki Mataora is focused on translating basic science into real outcomes in healthcare."
"TTM aims to create more high-paying jobs and successful medtech companies in New Zealand."
"The Research Acceleration Program (RAP) provides funding and support for researchers and spin-out companies."
Chapters
00:00 Introduction and Background of Te Titoki Mataora (TTM)
03:46 Collaboration for Medical Technology Translation
09:06 The Research Acceleration Program (RAP)
12:15 Future Aspirations for TTM -
Today’s guest is Charlotte Bradshaw, the Founder & CEO of Evrima Technologies.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
Evrima aims to solve the problem of finding patients for clinical trials by building networks of clinicians and integrating trial information into their workflow. The goal is to make it easier for healthcare providers to identify eligible patients and provide them with trial options, with the ultimate vision is to have a measurable impact on the clinical trial value chain, enabling research to happen faster and getting treatments to the people who need them.
Evrima offers three products:
evripath, a referral network that connects sites, CROs, and sponsors to pharmacists and GPsevrilink, a recruitment platform that securely delivers participant referrals to sites, andevriquest, innovating recruitment marketing solutionsIn this episode, Charlotte describes how the company was built based on feedback from clinical trial teams who struggled with outdated tools like spreadsheets, and emphasizes the importance of technology adoption and collaboration in the clinical trial industry.
Charlotte also shares her experiences and challenges in starting and growing the business, including the decision to raise capital and the need for continuous learning and support.
You can find out more about Charlotte Bradshaw and Evrima here: https://www.linkedin.com/in/charlottebradshaw/ https://www.linkedin.com/company/evrimatechnologies/posts/?feedView=all https://www.evrima.com/
Podcast Takeaways:
Raising awareness about clinical trials is crucial for the advancement of medicine and human health.Evrima aims to make it easier for healthcare providers to access trial information and provide it to their patients.Integrating clinical trial data into existing systems can help identify eligible patients and streamline the recruitment process.The ultimate goal is to have a measurable impact on the clinical trial value chain and ensure that treatments reach the people who need them.The clinical trial industry needs to adopt and embrace technology to overcome challenges and improve processes.Starting and growing a business requires making pivotal decisions, learning quickly, and seeking support from mentors and advisors.Entrepreneurs in the clinical trial space should prioritize mental health and self-care and build a strong network for guidance and support.Chapters
00:00 Introduction and Background
06:11 Identifying the Pain Points in Clinical Research
09:31 The Traditional Approach to Finding Patients for Clinical Trials
11:48 Integrating Clinical Trial Information into Healthcare Practice
15:24 Measuring the Impact of Clinical Trial Solutions
21:36 Raising Awareness and Reducing Taboos
24:22 The Vision and Impact of Evrema
29:01 Challenges and Decisions in Starting and Growing a Business
32:13 Prioritizing Progress over Perfection
36:30 Raising Capital and Building a Support Network
43:30 Expanding the Reach of Evrima and the Future of Clinical Trials
46:28 Lessons Learned and Advice for Budding Entrepreneurs
Keywords:
clinical trials, awareness, patients, doctors, Evrema, barriers, participation, healthcare providers, integration, digital phenotype, impact, Evrima, EveryPath, EveryLink, referral network, recruitment platform, clinical trials, technology adoption, collaboration, starting a business, raising capital, challenges, continuous learning, support
Subscribe for free on Spotify - https://open.spotify.com/show/3Vet6Hn8XFMhprr2LrY3XS G
et in touch in the comments below or head to: https://www.instagram.com/_good_clinical/
Developing Technology to Streamline Clinical Trial Recruitment | Charlotte Bradshaw | Ep 26 -
Today’s guest is John Robson (JR), General Manager at Bridgewest Ventures NZ, and Managing Director of BioOra, a company that is automating the manufacture of CAR T-cells.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
The development of new technologies, whether it be medical or otherwise, requires a lot of resources. One of those resources is capital - financial capital. Financial capital for new ventures can come in many forms, including loans from Mom & Pop or the bank, angel investment, grants, or private capital.
One of the forms of private capital is venture capital, or VC. VC is characterised by investment in young companies with growth potential. But it's not just about the money. As JR puts it, no founder has every said they were successful because they had an endless supply of money...
In this episode, and I discuss:
The idiosyncrasies of the New Zealand start-up ecosystemVenture Capital's role to play in the ecosystemBridgwest's portfolio of companies working in the CAR space....and much much more.
You can find out more about John Robson and Bridgewest Ventures here:
LinkedIn - John Robson (JR)
LinkedIn - Bridgewest Ventures
https://bridgewest.ventures/
https://bioora.com/
Timestamps:
00:00 Teaser
00:30 Introduction
02:20 True Venture Capital vs. Vulture Capital
05:00 Early Stage / Deep Tech Investment
09:20 Improving the status quo - Infrastructure, Human Capital, Regulation
16:00 Money follows success
20:33 Shaping the world around you
23:15 Doing more with less
25:20 It's not just about the money
26:10 Celebrating, and advertising, our successes
29:45 Where does the money come from - Bridgewest edition
34:30 Industry average is one in ten companies
36:20 Early VC - TechTransfer Office involvement
40:00 Founder Equity - Bespoke arrangements
44:00 Bridgewest's CAR portfolio companies
53:15 Advice for Biotech entrepreneurs
To get in touch head to: https://www.instagram.com/_good_clinical/
Vulture Capital vs. True Venture Capital | John Robson | Ep 25
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth -
Today’s guest is Cameron Quilter, and Clinical Research Associate (CRA) at Novotech.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
In most Clinical Research Trials, there are three players:
The "Sponsor" - the entity that is funding the research and could be a pharmaceutical company, insitute or other non-profit entity;The "Site" - hospital or private research clinical that is carrying out the research and administering the treatments and other procedures to the patients, andThe "Contract Research Organization", or CRO, which is delegated various responsibilities on behlaf of the sponsor.The Clinical Research Associate, or CRA, is the workhorse of the Sponsor or CRO. CRAs work with staff at the "site" to ensure that the research is conducted according to local and international regulatory and Ethical requirements, and helping to ensure that safety, rights and well-being of research participants are the priority.
CRAs need to have keen attention to detail, a solid understanding of human biology and pharmaceutical science, and an ability to work well with all different personality types and manage the multitude of different "stakeholders". Oh, and being comfortable travelling to different cities every other day is a plus too!
Despite this, the hardest part about a CRA role? Can often be getting a role in the first place! Yet once one has their foot in the door, the CRA role provides a spring-board to take your Science Career in a multitude of different directions.
In this episode, Cameron and I discuss:
How to get land a Clinical Research Associate (CRA) jobThe different careers paths that one can take after a CRA careerSome thoughts on the future of Clinical Research and biotechnology in New Zealand and AustraliaYou can find out more about Cameron and Novotech here:
LinkedIn - Cameron Quilter
LinkedIn - Novotech
Cameron Quilter | How to get a CRA job and how to make the most of it | Ep 24
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth -
Today’s guest is Dr Zahra Champion, Executive Director of BiotechNZ.
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
Biotechnology is a broad category, and ranges from the use of yeast to brew beer, something humans have been doing for the past 9,000 years to manipulating our DNA to fight cancer, something we have been doing for last 20 years. Biotech is a platform technology that sits across all sectors - animal health, agriculture, human health etc.
Modern Biotechnology has the potential to change lives and economies. New Zealand is at a crossroads, after years of onerous regulations stifling advancement in this area, the new government have made moves to re-vamp these regulations to unlock capacity.
But to make a modern biotechnology industry happen, you don't just need benign regulations, you also need smart and motivated individuals and even smarter money. I
n this episode, Dr Champion and I discuss:
What is Biotechnology and where the opportunities areWhat we can learn from other countries that have developed frameworks to support the implementation of biotechnologyAdvice for budding and future biotech entrepreneursYou can find out more about Dr Champion and BiotechNZ here:
LinkedIn - Zahra Champion
BioTECH NZ
Timestamps:
00:00 Teaser
00:30 Introduction
02:50 Regulatory framework holding Biotech back
04:10 Negative implications of not having a Biotech industry
05:30 What is Biotech
08:50 Taking gene technologies from the lab to trial
13:19 Medicinal cannabis: a case study
14:00 New Zealand can adopt the gold-standard of regulations from the world
15:15 Opportunity-cost of NOT having a thriving biotechnology industry
18:20 Biotechnology is expensive
21:00 Early-stage funding is available, but late-stage is not
25:00 Developing a New Zealand flavour for biotech
29:00 Australia vs. New Zealand
31:15 Tall poppy syndrome & showing the world that we are open for business
33:40 Short vs. Long-termism
37:20 Aroa Biosurgery & Neuren Pharmaceuticals set an example
38:50 Smart money = not repeating the same pitfalls
40:30 Internal monologue or dialogue
44:50 Advice for Biotech Entrepreneurs
Dr Zahra Champion | The Future of Biotechnology in New Zealand Ep 23 | Ep23
#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #chatgcp #healthcare #clinicaltrials #goodclinical #goodclinicalnetwork #goodclinicalmedia -
Today’s guest is Dr Paul Hamilton, Clinical Director of Early Phase Research at Pacific Clinical Research Network (PCRN).
This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/
New medicines are first studied in animals before they are tested in humans. Animal testing provides an insight into the efficacy, safety and tolerability of the new medicine. But before a new medicine can be tested on their intended patient population, the so-called "First In Human" (FIH) testing needs to take place. This is typically done in Normal Healthy Volunteers (NHVs) - i.e., a group of healthy individuals, not taking any prescription medications. Once the safety and tolerability of a new medicine has been substantiated in NHVs, only then can the medicine be tested in a patient.
These types of trials are Phase 1 and 1b/2a trials, respectively, and are collectively called "Early Phase Trials". Early Phase trials are an exciting part of the clinical trials spectrum, as this is where the "Proof of Concept" is first determined. And, as Dr Paul Hamilton explains, can deliver impressive health improvements if the technology works as expected.
As time progresses, new medicines become more targeted as we enter the era of "precision medicine". The drugs of tomorrow, are being tested today. The argument for participating in a clinical trial as a patient with a disease is compelling as Dr Hamilton explains in this podcast.
In this episode, Dr Hamilton and I discuss:
The importance of Early Phase Clinical TrialsWhy clinical trials need to be seen as a component of a patient's overall healthcare journey Future opportunities and challenges in the Clinical Research/Trials space in New ZealandYou can find out more about Dr Hamilton and Pacific Clinical Research Network (PCRN) here:
Pacific Clinical Research Network
Paul Hamilton - LinkedIn
PCRN - LinkedIn
Timestamps:
00:00 Teaser
00:22 Introduction
01:30 Pivoting from from medicine and clinical research
08:40 Paul's defining moment in clinical trials - Sofosbuvir
12:30 Danicopan
15:50 The future of medicine starts with Early Phase research
21:30 Early Phase vs. Late Phase
23:30 Setting up a new Early Phase research location
29:25 Clinical trials have a responsibility for delivering healthcare
33:00 Designing good early phase studies
37:00 The Future of Clinical Trials in New Zealand
44:25 Advice for getting into clinical research
Dr Paul Hamilton | Clinical Trials are driving the Future of Medicine and Healthcare | Ep 22
innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials -
Today’s guest is Dr Brian Ward, Founder and CEO of Aroa Biosurgery, an ASX-listed, biotech company with with a ~$200 m AUD market capitalization.
This episode is brought to you by SAPRO Consulting.
Aroa Biosurgery is a New Zealand-based, ASX-listed biotech company that develops and commercializes novel products that promote wound healing and soft-tissue repair. Their proprietary products, developed from tissue taken from the fore-stomach of sheep, provide the body with structural and biological components that provide a head start in the healing process.
Biotech is a hard business. It's expensive, time-consuming and the road to success is fraught with difficulty and complexity and many biotech companies never make it to profitability. Despite this, there are a number of biotech entrepreneurs with such a fire within them that the odds seem to be in their favour.
Dr Ward's and the Aroa Biosurgery story is remarkable. From the idea, to the product, the manufacturing and commercialzation, the various challenges that have arisen have been overcome resulting in a compelling success story that would inspire any current, or aspiring, biotech entrepreneur.
In this episode, Dr Ward and I discuss:
1. The eureka moment that made Brian pivot from clinical practice to entrepreneurial endeavour
2. The science and technology that underpins their novel products
3. Brian's tips for aspiring biotech entrepreneurs - just get started, understand it will not be easy, be prepared for a "game of attrition" and surround your self with people smarter than you.
You can find out more about Brian Ward and Aroabiosurgery here:
LinkedIn - Dr Brian Ward
LinkedIn - Aroa Biosurgery
Aroa Biosurgery Website -
Today’s guest is Madhu Vyas, Theranostics Site Leader at Mercy Radiology, and Programme Lead at Unitec.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
Nuclear Medicine, Molecular Imaging and Radiochemistry sound like terms pulled straight from a science fiction novel. Yet the use of radioactive materials for the purposes of diagnosing and treating disease - collectively referred to as theranostics (therapy + diagnostics) - are commonly place and an exciting field of discovery and development.
But with so many different radioactive materials to choose from, each with their own characteristics, how do researchers and physicians choose the right one? And how is the radiation targeted to the desired organ or diseased tissue without damaging normal tissue?
In this episode, Madhu and I discuss:
1. The origins of nuclear medicine, molecular imaging and "theranostics"
2. How radioactive material is targeted to different tissues within a patient for the purposes of either diagnosis or therapy
3. What we can expect for the future of an area of medicine that is now hitting it's stride
Madhu Vyas' passion for this field is palpable. When not working as the Theranostics Site Leader at Mercy Radiology, he is teaching the next generation of Medical Imaging technicians and also completing a PhD. Clearly, Madhu has discovered a way to wring more than 24 hours out of a single day!
You can find out more about Madhu, Mercy Radiology & Unitec:
https://www.linkedin.com/in/150880/
https://www.linkedin.com/company/mercy-radiology/ https://radiology.co.nz/ https://www.linkedin.com/school/unitecnz/
https://www.unitec.ac.nz/
#newzealand #radiochemistry #radiation #radiationtherapy #theranostics #nuclear #nuclearimaging #molecularimaging #theranos #innovation #podcast #commercialization #science #entrepreneurship #innovation -
Today’s guest is Will Charles, the Executive Director of Investment at UniServices.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
UUniversities are a great place to get higher education, but they're also places where new ideas, concepts and technologies first take root. But how do new ideas make their way from the academic setting to the commercial setting?
UniServices is wholly owned by the University of Auckland and is a not-for-profit, stand-alone company that provides support to researchers by helping them secure the funding and connections that can help them make a positive impact.
Will Charles (great surname) has built an amazing career over time, tacking on new skills to make him a force in the world of commercialization of science and ensuring that University Intellectual Property simply doesn't gather dust on a shelf.
In this episode, Will and I discuss:
What Technology Transfer isHow UniServices supports acadmics and entrepreneurs alike3. Will's recommendations for budding entrepreneurs - top tip: Get in early, make mistakes in a low-risk environment (i.e., while at university).You can find out more about Will and UniServices here:
https://www.linkedin.com/in/will-charles-b4005a5/ https://www.uniservices.co.nz/ https://www.linkedin.com/company/auckland-uniservices-limited/
#newzealand #technologytransfer #innovation #podcast #commercialization #science #entrepreneurship #innovation -
Today’s guest is Dr Rohit Katial, a Research Physician involved in Early Phase Clinical Trials in New Zealand.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
Unfortunately, in New Zealand our access to modern medicines is well behind our OECD peers, and it typically takes 10 years before a new medicine is funded by Pharmac after being approved by Medsafe. Thus, Clinical Research is starting to do more and more of the heavy lifting to fill the gap between need and access.
An interesting component of ClinicalResearch is Early Phase trials - which range from firstinhuman trials, to the initial studies in patients i.e., single ascending dose or multiple-ascending dose studies, aptly shortened to SAD or MAD trials.
New Zealand is increasingly becoming an attractive place to conduct Early Phase research, by virtue of our diverse & young population, less onerous regulatory requirements and skilled workforce.
Despite this, early phase ClinicalResearch is not an obvious career choice for those studying or participating in medicine. This is a challenge that will need to be addressed if we are to make the most of the opportunity that is before us.
In this episode, Dr Rohit Katial and I discuss:
1. His journey from mainstream medicine to early phase clinical research
2. the core skillset that is needed to be proficient as an early phase clinical trials investigator
3. Some of the exciting trials Rohit has been a part of....hint: gene editing
You can find out more about Rohit and New Zealand Clinical Research here: https://www.linkedin.com/in/rohit-katial/ https://www.linkedin.com/company/nzcr-christchurch/ https://www.nzcr.co.nz/
#newzealand #clinicalresearch #innovation #podcast #clinicalresearchassociate #principalinvestigator #clinicaltrials #CRISPr #geneediting -
Today’s guest is Shamubeel Eaqub, and economist, author and commentator.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
In this episode Shamubeel and I discuss New Zealands productivity has not kept up with our OECD peers. Reasons for this include some things we cannot change, such as the fundamental realities of our small population and remote location at the bottom of the South Pacific, but also things we can, including policy settings, institutions, incentives, long-termism, and culture.
Some very impressive companies have been built in New Zealand by some truly great minds, yet it would seem that the success of these companies has not been due to the settings, but rather in spite of them.
https://open.spotify.com/episode/2zKFT444A8FhtpnWlJx2Ci?si=6d1621a6b10e41ba
You can find out more about Shamubeel here:
https://www.linkedin.com/in/eaqub/
#newzealand #incentives #innovation #country #commercialization #government #economy #productivity #universities #biotech #risk #shorttermism #choices #geography -
Today’s guest is Natalia Lopez, the Co-Founder and Chief Operations Officer of Kitea Health.
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
In our first episode of 2024, we are picking up where we left of in 2023 with another guest from Kitea Health - this time with Chief Operations Officer Natalia Lopez.
We talk about Natalia's journey from the automotive industry to Medical technology, the importance of developing meaningful skills to bridge the gap between the science "bench-top" and the patient, and dive a little deeper into the technology that underpins Kitea's novel deveice of the monitoring of Physiological Pressure.
This was a very inspiring discussion, and we're looking forward to the day where Kitea's vision for proactive healthcare is a reality.
You can find out more about Natalia Lopez and Kitea Health here:
https://www.linkedin.com/in/natalia-lopez-a34457147/
https://www.linkedin.com/company/kitea-health/
https://www.kiteahealth.com/
#research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch -
This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/
Today’s guest is Dr Simon Malpas, the Co-founder and CEO of Kitea Health.
Simon is a distinguished New Zealand scientist and entrepreneur, and has co-founded three successful medical device & life science companies from his research, including Kitea Health, a Start up company transforming healthcare for people living with chronic conditions via the monitoring of physiological pressure.
In this episode we discuss:
How Kitea’s technology can help us graduate from a Reactive to a Proactive model of healthcare for chronic conditionsKitea’s plans to address the unmet clinical need in patients with hydrocephalusKitea’s commercialization journey to date, including their upcoming first in human clinical trial, slated for 2024.This was a super interesting discussion, with plenty of insights for budding life science entrepreneurs, and for someone with a passion for clinical research I will be watching their progress closely over the 2024.
You can find out more about Simon Malpas and Kitea Health here: https://www.linkedin.com/in/simon-malpas-65052268/ https://www.linkedin.com/company/kitea-health/
https://www.kiteahealth.com/
research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch Subscribe for free on Spotify - https://open.spotify.com/show/3Vet6Hn8XFMhprr2LrY3XS
Get in touch in the comments below or head to: https://www.instagram.com/chat_gcppodcast/ - Laat meer zien
